BR112021025806A2 - Métodos para produzir um anticorpo da subclasse igg1 humana cultivando uma célula cho e uso da remoção de sítios de splice de doador não pareados em uma parte de uma sequência de ácido nucleico de humano ou hamster - Google Patents

Métodos para produzir um anticorpo da subclasse igg1 humana cultivando uma célula cho e uso da remoção de sítios de splice de doador não pareados em uma parte de uma sequência de ácido nucleico de humano ou hamster

Info

Publication number
BR112021025806A2
BR112021025806A2 BR112021025806A BR112021025806A BR112021025806A2 BR 112021025806 A2 BR112021025806 A2 BR 112021025806A2 BR 112021025806 A BR112021025806 A BR 112021025806A BR 112021025806 A BR112021025806 A BR 112021025806A BR 112021025806 A2 BR112021025806 A2 BR 112021025806A2
Authority
BR
Brazil
Prior art keywords
human
nucleic acid
culturing
producing
cho cell
Prior art date
Application number
BR112021025806A
Other languages
English (en)
Portuguese (pt)
Inventor
Katharina Lutz
Stefan Klostermann
Stefan Seeber
Ulrich Goepfert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112021025806A2 publication Critical patent/BR112021025806A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112021025806A 2019-06-28 2020-06-25 Métodos para produzir um anticorpo da subclasse igg1 humana cultivando uma célula cho e uso da remoção de sítios de splice de doador não pareados em uma parte de uma sequência de ácido nucleico de humano ou hamster BR112021025806A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19183171 2019-06-28
PCT/EP2020/067770 WO2020260431A1 (en) 2019-06-28 2020-06-25 Method for the production of an antibody

Publications (1)

Publication Number Publication Date
BR112021025806A2 true BR112021025806A2 (pt) 2022-02-08

Family

ID=67253661

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025806A BR112021025806A2 (pt) 2019-06-28 2020-06-25 Métodos para produzir um anticorpo da subclasse igg1 humana cultivando uma célula cho e uso da remoção de sítios de splice de doador não pareados em uma parte de uma sequência de ácido nucleico de humano ou hamster

Country Status (11)

Country Link
US (1) US20220220500A1 (https=)
EP (1) EP3990484A1 (https=)
JP (2) JP7511591B2 (https=)
KR (1) KR102900433B1 (https=)
CN (1) CN113993888B (https=)
AU (1) AU2020304841B2 (https=)
BR (1) BR112021025806A2 (https=)
CA (1) CA3143803A1 (https=)
IL (1) IL289210A (https=)
MX (1) MX2021015193A (https=)
WO (1) WO2020260431A1 (https=)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CN100427603C (zh) 1999-10-04 2008-10-22 麦迪卡格公司 调控外源基因转录的方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
JP2006238894A (ja) * 2000-02-15 2006-09-14 Amgen Inc 線維芽細胞成長因子−２３分子およびその使用
ATE318908T1 (de) 2000-05-18 2006-03-15 Geneart Gmbh Synthetische gene für gagpol und deren verwendungen
US7879540B1 (en) 2000-08-24 2011-02-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
AU2003206684A1 (en) 2002-02-20 2003-09-09 Novozymes A/S Plant polypeptide production
US20040005600A1 (en) 2002-04-01 2004-01-08 Evelina Angov Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
US20060024670A1 (en) 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
EA200700751A1 (ru) * 2004-10-05 2008-06-30 Элан Фарма Интернэшнл Лимитед Способы и композиции для улучшения продуцирования рекомбинантного белка
EP2021489A2 (en) 2006-05-30 2009-02-11 Dow Global Technologies Inc. Codon optimization method
DK2423315T3 (en) 2006-06-29 2015-04-13 Dsm Ip Assets Bv A method for obtaining enhanced polypeptide expression
LT2167540T (lt) * 2007-06-29 2018-04-25 F. Hoffmann-La Roche Ag Sunkioji grandinė mutantė, pagerinanti imunoglobulino gamybą
US7947495B2 (en) * 2007-11-01 2011-05-24 Abbott Biotherapeutics Corp. Immunoglobulin display vectors
AU2009314111A1 (en) * 2008-11-12 2010-05-20 Merck Sharp & Dohme Corp. BetaGI-IgG intron for enhanced anti-IGF1 R expression
US20100303776A1 (en) * 2009-04-16 2010-12-02 The University Of North Carolina At Chapel Hill Methods and compositions for regulated expression of multiple nucleic acids
KR20130013435A (ko) 2011-07-28 2013-02-06 차의과학대학교 산학협력단 태반-유래 줄기세포의 증식방법
CN109810188A (zh) * 2011-12-21 2019-05-28 弗·哈夫曼-拉罗切有限公司 用于克隆和表达关联抗体可变区基因区段的快速方法
EP2794878B1 (en) * 2011-12-22 2020-03-18 F.Hoffmann-La Roche Ag Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JP6224077B2 (ja) * 2012-04-17 2017-11-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 改変された核酸を用いてポリペプチドを発現させるための方法
SG10201913396RA (en) * 2014-02-28 2020-03-30 Ichnos Sciences SA Expression constructs and methods for selecting host cells expressing polypeptides
KR20180018659A (ko) * 2015-06-08 2018-02-21 코닝 인코포레이티드 전달이 없는 마이크로엘이디 디스플레이

Also Published As

Publication number Publication date
EP3990484A1 (en) 2022-05-04
IL289210A (en) 2022-02-01
JP7511591B2 (ja) 2024-07-05
KR102900433B1 (ko) 2025-12-15
AU2020304841B2 (en) 2024-08-15
US20220220500A1 (en) 2022-07-14
JP2023183417A (ja) 2023-12-27
CN113993888A (zh) 2022-01-28
MX2021015193A (es) 2022-01-18
JP2022538178A (ja) 2022-08-31
CA3143803A1 (en) 2020-12-30
KR20220024954A (ko) 2022-03-03
AU2020304841A1 (en) 2021-12-23
WO2020260431A1 (en) 2020-12-30
CN113993888B (zh) 2026-01-06
JP7835713B2 (ja) 2026-03-25

Similar Documents

Publication Publication Date Title
BR112018006961A2 (pt) composição de fortalecimento para cabelos e método para fortalecer os cabelos
BR112018075688A2 (pt) anticorpos anti-c5 e métodos de uso
CY1123800T1 (el) Μεθοδος για την εκτελεση ενδο-προβλεψης χρησιμοποιωντας προσαρμοζομενο φιλτρο
MX2021000934A (es) Linfocitos t que contienen nef y métodos para producirlos.
HRP20200893T1 (hr) Pripravci stanične kulture s antioksidansima i postupci proizvodnje polipeptida
MX384138B (es) Anticuerpos anti-c5 y métodos para su uso.
BR112021019411A2 (pt) Métodos para a produção de células car-nk e uso das mesmas
NZ601743A (en) Methods for identifying and isolating cells expressing a polypeptide
MX2022014885A (es) Anticuerpos anti-c5 y metodos de uso.
BR112021014645A2 (pt) Método de edição de genes
BR112021024946A2 (pt) Célula de mamífero, método para produzir uma célula de mamífero implantável, e, uso de uma célula de mamífero
BR112013000515A2 (pt) método para prodduzir um composição de fator von willebrand recombinante (rvwf), sobrenadante de cultura de célula, e, composição do fator von willebrand recombinante (rvwf)
MX2014010021A (es) Anticuerpos biespecificos igg4 modificados de secuencia asimetrica.
BR112015017174A2 (pt) preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico
MX2021003654A (es) Metodo para seleccionar neoepitopes.
AR096058A1 (es) Tratamiento de una formación subterránea con una composición que incluye un microorganismo o un compuesto generado por dicho microorganismo
WO2019108676A8 (en) Systems and methods of formal verification
BR112021020867A2 (pt) Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
MX2020012649A (es) Neoantígenos especificos de tumor y métodos de uso de estos.
EP3103810A3 (en) Modified variable domain molecules and methods for producing and using them
BR112021025806A2 (pt) Métodos para produzir um anticorpo da subclasse igg1 humana cultivando uma célula cho e uso da remoção de sítios de splice de doador não pareados em uma parte de uma sequência de ácido nucleico de humano ou hamster
D’Agostino et al. Potential of biofermentative unsulfated chondroitin and hyaluronic acid in dermal repair
WO2020154548A3 (en) Antibodies specific to delta 1 chain of t cell receptor
BR112021018691A2 (pt) Géis homogêneos injetáveis compreendendo formas múltiplas de ácido hialurônico e métodos para sua fabricação
BR112023011689A2 (pt) Método para obter uma célula produtora de anticorpos, anticorpo, e, célula hospedeira de mamífero

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]